Risk and Return

Phantom Neuro specializes in developing innovative muscle-machine interfaces that enhance robotic limb rehabilitation. The company focuses on creating solutions that improve mobility for users by integrating neurotechnology with robotic systems, aiming to facilitate precise control of robotic limbs and enable more natural movement.

Modality.AI, Inc. is a healthcare technology company based in San Francisco, California, founded in 2018. It specializes in AI-powered solutions that enhance the efficiency of clinical trials for neurological and mental health therapies. The company's platform utilizes conversational AI to engage patients through naturalistic spoken interaction, allowing for continuous health assessments anytime and anywhere. By analyzing multimodal data, including audio-visual biomarkers, Modality.AI provides objective measures that correlate with clinical outcomes. This innovative approach enables pharmaceutical companies to conduct self-driven assessments and improve the monitoring of health conditions, ultimately facilitating more effective clinical trials.

Phantom Neuro specializes in developing innovative muscle-machine interfaces that enhance robotic limb rehabilitation. The company focuses on creating solutions that improve mobility for users by integrating neurotechnology with robotic systems, aiming to facilitate precise control of robotic limbs and enable more natural movement.

Prepared develops an AI-powered platform that enhances emergency response by streamlining call-taking, dispatch, and quality assurance. The solution provides real-time access to video, GPS location, and texts from mobile 911 callers, along with automated language translation and real-time QA tools. These capabilities help public safety agencies reduce response times, improve dispatch efficiency, and better serve diverse communities. Prepared emphasizes people, mission, and values to maximize impact on public safety across communities.

HAAS Alert is a prominent provider of mobility and smart city data services focused on enhancing safety for emergency crews, drivers, and the general public through Cellular Vehicle-to-Vehicle (V2V) communication. The company's Safety Cloud delivers real-time data that connects first responders and various fleets with motorists and autonomous vehicles, helping to prevent collisions and minimize traffic delays. HAAS Alert's platform issues preemptive notifications to drivers, alerting them to the approach of emergency vehicles via their car dashboards or smartphones. Additionally, the service supports smart city initiatives by providing valuable traffic information to government officials, aiding in infrastructure planning and real-time traffic management. HAAS Alert collaborates with the U.S. Department of Homeland Security on innovative safety solutions and has garnered support from notable safety organizations.

Modality.AI, Inc. is a healthcare technology company based in San Francisco, California, founded in 2018. It specializes in AI-powered solutions that enhance the efficiency of clinical trials for neurological and mental health therapies. The company's platform utilizes conversational AI to engage patients through naturalistic spoken interaction, allowing for continuous health assessments anytime and anywhere. By analyzing multimodal data, including audio-visual biomarkers, Modality.AI provides objective measures that correlate with clinical outcomes. This innovative approach enables pharmaceutical companies to conduct self-driven assessments and improve the monitoring of health conditions, ultimately facilitating more effective clinical trials.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through the integration of patient neurobiology into the drug development process. Utilizing an AI-enabled biomarker platform, the company combines diverse information about patients' brain activity and behavior to create personalized and effective treatment options. Alto Neuroscience is developing several clinical assets, including ALTO-100, ALTO-202, ALTO-101, and ALTO-300, primarily targeting depressive disorders and schizophrenia, identified through independent brain-based biomarkers. By moving away from traditional trial-and-error methods, the company aims to align its innovative therapies with the specific needs of patients, ultimately improving the management of mental health conditions.